Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-02-23

Clinical Trial Update: Ruxolitinib in Patients With Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of ruxolitinib in patients with breast cancer was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-02-23